Galectin-3
For informational purposes only — not medical advice. Always consult a qualified healthcare provider before making changes to your health regimen. Full disclaimer →
- Galectin-3 is the primary driver of cardiac fibrosis — the cellular basis of heart failure. Unlike other cardiovascular markers that reflect atherosclerosis or inflammation, galectin-3 reflects a different disease process: the progressive fibrotic stiffening of the heart muscle. This is particularly relevant to heart failure with preserved ejection fraction (HFpEF) — the form of heart failure where the heart pumps normally but cannot relax adequately — which is now the dominant form of heart failure in older adults.
- Elevated galectin-3 predicts incident heart failure in people without known cardiac disease. The Framingham Heart Study and other prospective cohorts have found that galectin-3 in the upper quartile of the population distribution predicts a 2–3× higher rate of new heart failure over 10-year follow-up, independent of conventional risk factors. It identifies people at risk for the fibrotic form of heart failure years before symptoms develop.
- Galectin-3 reflects organ fibrosis systemically — not just in the heart. The same fibrotic signaling that galectin-3 drives in the heart also occurs in the kidneys (contributing to CKD progression) and the liver (contributing to NASH and cirrhosis progression). Elevated galectin-3 may therefore reflect a systemic pro-fibrotic state that accelerates organ aging across multiple systems simultaneously.
- Galectin-3 rises with kidney function decline. Galectin-3 is partially renally cleared, meaning reduced GFR causes galectin-3 accumulation independent of production rate — the same confound as TMAO and cystatin C. Interpreting galectin-3 without accounting for kidney function can misattribute elevated levels to cardiac fibrosis when kidney clearance impairment is the primary driver.
- No pharmacological interventions reliably reduce galectin-3. Unlike cholesterol or blood pressure, there is currently no established medication that specifically targets galectin-3. Spironolactone modestly reduces galectin-3 in heart failure patients. The primary intervention is addressing the underlying drivers: chronic inflammation, metabolic syndrome, and hypertension — which are the upstream causes of the macrophage activation that produces galectin-3.
The Biomarker of Organ Aging You've Never Heard Of
Most cardiovascular biomarkers address atherosclerosis — the buildup of cholesterol-rich plaques in arterial walls. ApoB, LDL, Lp(a), hsCRP, fibrinogen, and Lp-PLA2 all reflect, in different ways, the process of plaque formation and its inflammatory consequences. But atherosclerosis is not the only way the cardiovascular system ages.
Fibrosis — the progressive replacement of functional cardiac muscle with inert collagen scar tissue — is an equally important but far less discussed pathway of cardiac aging. It is the primary driver of heart failure with preserved ejection fraction, the dominant form of heart failure in adults over 65. And it begins decades before symptoms appear.
Galectin-3 is the most clinically validated biomarker of this fibrotic process. Produced by activated macrophages within fibrotic tissue, it both reflects and drives the collagen deposition that stiffens the heart, impairs kidney tubular function, and advances liver fibrosis. Measuring it in an asymptomatic adult provides a window into the fibrotic burden of vital organs that no other standard biomarker provides.
Galectin-3 Mechanism: How Macrophages Scar the Heart
The cellular mechanism of galectin-3-driven fibrosis is well-characterized. In response to chronic cardiac stress — from hypertension, metabolic syndrome, repeated ischemic insults, or aging itself — resident and recruited macrophages in the myocardium become activated and upregulate galectin-3 expression. Secreted galectin-3 then acts on cardiac fibroblasts via cell-surface receptors, stimulating their transformation into myofibroblasts — the cells primarily responsible for collagen synthesis and deposition.
The result is progressive replacement of the elastic, compliant cardiac extracellular matrix with rigid collagen fibers. The cardiomyocytes themselves may be intact and capable of contracting normally, but the stiff collagen matrix prevents the heart from relaxing adequately during diastole — producing the characteristic diastolic dysfunction of HFpEF.
The Framingham Heart Study prospectively demonstrated that galectin-3 in the highest quartile was associated with a 2.4× higher risk of incident heart failure over 9.8 years of follow-up in individuals free of heart failure at baseline, after adjustment for age, sex, and conventional risk factors. 1
| Level | Range | Interpretation | Notes |
|---|---|---|---|
| Optimal | < 12 ng/mL | Low fibrotic burden | Lower half of normal range; lowest event rates |
| Borderline | 12–17.8 ng/mL | Elevated — warrants attention | Address upstream drivers; retest in 6–12 months |
| Elevated | > 17.8 ng/mL | FDA-cleared heart failure risk threshold | Cardiac evaluation warranted; assess kidney function |
Already have your lab results? See how your Galectin-3 and other markers score on a longevity scale — in under 60 seconds.
Analyze My Biomarkers →Galectin-3 Across Organ Systems
While galectin-3's cardiovascular applications are best established, its role in fibrosis extends to other organs that age through the same mechanism. In the kidneys, galectin-3 drives tubular fibrosis and is elevated in CKD patients proportional to disease severity — and it predicts CKD progression independently of GFR. In the liver, galectin-3 is elevated in NASH and correlates with fibrosis stage — some researchers propose it as a non-invasive fibrosis marker that could reduce the need for liver biopsy. In the lungs, galectin-3 drives idiopathic pulmonary fibrosis and is elevated in proportion to disease severity.
This multi-organ relevance of galectin-3 supports a conceptual framework in which chronic systemic inflammation and metabolic dysfunction drive macrophage-mediated fibrosis in multiple vital organs simultaneously — aging the heart, kidneys, and liver in parallel. A person with metabolic syndrome, hypertension, and chronic low-grade inflammation may be quietly developing cardiac, renal, and hepatic fibrosis concurrently, with galectin-3 as the common upstream signal.
Sources
- Wang TJ, et al. "Circulating Galectin-3 and Incident Heart Failure in Community-Dwelling Adults." Circulation: Heart Failure, 2012. PubMed →
| Range Type | Value (ng/mL) | Notes |
|---|---|---|
| Standard Clinical Range | < 17.8 ng/mL | Designed to identify disease risk — not longevity optimisation. |
| Longevity-Optimal Target | < 12 ng/mL |
Associated with reduced all-cause mortality and extended healthspan.
The FDA-cleared clinical cutoff for galectin-3 in heart failure (17.8 ng/mL) reflects a threshold validated for prognosis in diagnosed heart failure patients. In the general population without heart failure, longevity-focused practitioners target the lower half of the normal range — generally below 12 ng/mL — where prospective studies show the lowest event rates. Even within the 'normal' range, galectin-3 shows a dose-response relationship with cardiovascular and all-cause mortality. Galectin-3 rises with age, kidney function decline, and inflammatory burden — interpretation should account for these confounders.
|
Already have your results? See what your Galectin-3 and other markers reveal about your longevity in 60 seconds.
Analyze My Labs →Affiliate disclosure: we may earn a commission if you purchase through these links at no extra cost to you.
What is fibrosis and why does it matter for longevity?
Fibrosis is the pathological deposition of collagen and extracellular matrix proteins in tissues — essentially the formation of internal scar tissue in response to chronic injury or inflammation. While acute fibrosis is a normal part of wound healing, chronic fibrosis replaces functional tissue with non-functional collagen matrix, progressively reducing the organ's ability to perform its physiological role. In the heart, fibrosis reduces compliance and increases stiffness — the heart can still contract (ejection fraction may be preserved) but cannot relax adequately to fill properly, producing HFpEF. In the kidneys, fibrosis replaces functional nephrons, contributing to CKD progression. In the liver, fibrosis progresses from NASH to cirrhosis. Fibrosis in these vital organs represents a form of irreversible organ aging — once established, it is difficult to reverse. This is why detecting the early stages of fibrotic organ aging through galectin-3 — before organ dysfunction is measurable — is clinically meaningful.
What is HFpEF and why is galectin-3 particularly relevant to it?
Heart failure with preserved ejection fraction (HFpEF) is a form of heart failure in which the heart's pumping function (ejection fraction) is normal or near-normal, but the heart is stiff and cannot relax adequately to fill during diastole. This results in elevated filling pressures that produce the symptoms of heart failure — dyspnea, exercise intolerance, leg edema — without the reduced pumping function that characterizes classic heart failure. HFpEF now accounts for over 50% of heart failure cases and is growing in prevalence with aging populations and the obesity epidemic. Critically, HFpEF is primarily a disease of myocardial fibrosis and stiffness rather than cardiomyocyte loss — and galectin-3 directly drives the fibrosis that produces this stiffness. This is why galectin-3 is a particularly relevant biomarker for HFpEF risk, where conventional cardiac markers like troponin and BNP are less sensitive at early stages.
How does galectin-3 relate to inflammation markers like hsCRP?
Galectin-3 and hsCRP are related but distinct. hsCRP reflects the acute phase inflammatory response — it rises rapidly with infection, injury, or metabolic inflammation and falls when the stimulus resolves. Galectin-3 reflects a more chronic, tissue-level process: the macrophage-mediated fibrotic response that occurs with sustained inflammation or repeated injury. You can think of hsCRP as capturing the fire, while galectin-3 captures the scar tissue left by repeated fires. In practice, both can be elevated simultaneously in people with metabolic syndrome, chronic kidney disease, or advanced heart failure. But they can also diverge: normal hsCRP with elevated galectin-3 suggests active fibrotic tissue remodeling without systemic inflammation — a pattern seen in some people with advanced hypertensive heart disease or aging-related organ fibrosis.
Should people without heart failure get galectin-3 tested?
Galectin-3 is most commonly ordered in people with known or suspected heart failure, where it has the strongest evidence base. In a comprehensive longevity evaluation for an asymptomatic adult, galectin-3 adds meaningful information particularly for: people over 55 (when cardiac fibrosis begins to accumulate meaningfully); people with hypertension, diabetes, or metabolic syndrome (the strongest drivers of cardiac fibrosis); people with impaired kidney function (where galectin-3 reflects both cardiac and renal fibrotic burden); people with a family history of heart failure; and anyone with unexplained exercise intolerance or dyspnea. For a 45-year-old with no risk factors and a normal cardiovascular evaluation, galectin-3 adds less incremental value. It is best positioned as part of a comprehensive multi-marker evaluation rather than a standalone first-line test.
What can I do if my galectin-3 is elevated?
Because galectin-3 reflects chronic fibrotic organ remodeling driven by inflammation, hypertension, and metabolic disease, the primary interventions address these upstream drivers. Blood pressure control is arguably the most important modifiable factor — hypertension is the most common driver of cardiac fibrosis, and adequate blood pressure treatment slows galectin-3-mediated remodeling. Spironolactone (a mineralocorticoid receptor antagonist) has been shown in clinical studies to reduce galectin-3 levels and cardiac fibrotic markers in patients with heart failure and hypertension. Anti-inflammatory lifestyle interventions — exercise, Mediterranean diet, weight loss, smoking cessation — reduce the chronic inflammatory stimulus that activates galectin-3-producing macrophages. If elevated galectin-3 is accompanied by symptoms of heart failure or unexplained dyspnea, echocardiography and cardiology evaluation are warranted.